Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ninlaro | Ixazomib | Multiple Myeloma | Do not reimburse | Complete | ||
Alecensaro | Alectinib | Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Rituxan | Rituximab | Acute Lymphoblastic Leukemia | Do not reimburse | Complete | ||
Zaltrap | Aflibercept | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Zydelig | Idelalisib | Follicular Lymphoma | Do not reimburse | Complete | ||
Egrifta | Tesamorelin | Lipodystrophy, HIV-infected patients | Do not reimburse | Complete | ||
Darzalex | Daratumumab | Multiple Myeloma | Do not reimburse | Complete | ||
Imbruvica | Ibrutinib | Waldenstrom's Macroglobulinemia | Do not reimburse | Complete | ||
Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | ||
Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete |